Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05507541
Title TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic

diffuse large B-cell lymphoma activated B-cell type

primary mediastinal B-cell lymphoma

B-cell lymphoma

diffuse large B-cell lymphoma germinal center B-cell type

high-grade B-cell lymphoma double-hit/triple-hit

diffuse large B-cell lymphoma

follicular lymphoma


Pembrolizumab + TTI-622

Pembrolizumab + TTI-621

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.